| 1 |
35012940 | Functional impact and targetability of PI3KCA, GNAS, and PTEN mutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation. | 2022 Jan |
1 |
| 2 |
35363301 | Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. | 2022 Jun 1 |
2 |
| 3 |
33660194 | Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma. | 2021 Aug |
1 |
| 4 |
33789427 | LY3023414 inhibits both osteogenesis and osteoclastogenesis through the PI3K/Akt/GSK3 signalling pathway. | 2021 Apr |
2 |
| 5 |
34183163 | Synergistic effects of a combined treatment of PI3K/mTOR dual inhibitor LY3023414 and carboplatin on human endometrial carcinoma. | 2021 Sep |
3 |
| 6 |
34483936 | Samotolisib Attenuates Acute Liver Injury Through Inhibiting Caspase-11-Mediated Pyroptosis Via Regulating E3 Ubiquitin Ligase Nedd4. | 2021 |
2 |
| 7 |
31880826 | Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. | 2020 Mar 15 |
1 |
| 8 |
32578154 | Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer. | 2020 Dec |
2 |
| 9 |
32634436 | Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines. | 2020 Oct |
6 |
| 10 |
32894386 | Correction to: Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer. | 2020 Dec |
1 |
| 11 |
29474549 | PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay. | 2018 Apr 1 |
1 |
| 12 |
29636360 | A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer. | 2018 Jul 15 |
2 |
| 13 |
28184015 | Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations. | 2017 Feb 9 |
1 |
| 14 |
28623128 | Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth in vitro and in vivo. | 2017 Aug 19 |
6 |
| 15 |
29228741 | Autophagy inhibition sensitizes LY3023414-induced anti-glioma cell activity in vitro and in vivo. | 2017 Nov 17 |
3 |
| 16 |
27439478 | Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth. | 2016 Oct |
5 |
| 17 |
27823983 | Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts. | 2016 Nov 22 |
1 |